Tuesday, 2 September 2008

Superdoctors

You could call him the Indiana Jones of surgery. Steve Mannion, an orthopaedic surgeon, has devoted his life sentence to working in widespread and under-resourced corners of the world.



"Part of my reason for going into medicine was to work overseas. I was a bit of an adventurer. As a student, I did an elective on the Afghan-Pakistan border."


His sense of chance led him into working as a trauma and war surgeon for the Red Cross and medical aid agency Medecins Sans Frontiers.


Nowadays, Mr Mannion spends two weeks of every month at his job in Blackpool; and the other deuce weeks operative for charities in countries like Papua New Guinea and Sierra Leone.


He features in the last film in a three-part series called SuperDoctors which looks at the progress being made in medicine.




Medicine


The first two programmes focus on high-tech practice of medicine in the form of surgical robots and dearly-won stem cell therapy.


In contrast, presenter Robert Winston follows the operating surgeon to Malawi, one of the poorest countries on earth where the lifespan expectancy is around 40 years.


Mr Mannion's human ingenuity in treating people in places that have no technology or money has seen him cross over a medical frontier.


"It may not immediately be seeming that working in warfare zones or developing countries is somewhere you can push back medical frontiers or be very innovational, but I feel it's even more important in these situations," he said.








The surgeon believes you canful push the boundaries of medicine in poor countries



He maintains his mantra that "necessity is the mother of invention."


Around Malawi, the surgeon has several clinics for children and adults with clubfeet.


Like Britain, somewhere between one to two children per 1,000 are natural with this deformity.


Until lately the discourse in Britain has been extensive surgery, and when the treated child grows up they are much still in pain and scarred from the procedure.


In Malawi, however, Mr Mannion was one of only two surgeons for seven-spot million people in the northern area of the country.


Demand


To proceed up with demand, he had to come up with a new and non-surgical solution which he could train staff in the land to perform as well.


The surgeon constitute a slight known and scarcely secondhand physiotherapy treatment, called the Ponseti handling, which proven to be successful.


It involves gentle manipulation of the bones and stretching of the skin through casting, followed by the baby wearing a particular type of boots.


Quickly Mr Mannion spread the practice through clinics all over the country and soon evidence based on hundreds of cases showed that the treatment was excellent.


Not only that - it was better than the British treatment of surgery. He had stumbled across something big.


The computer program follows the Ponseti treatment - both in Africa and Britain - and tells the story of Steve's struggle to overcome deep-set traditions and practices to eventually cross a new medical frontier.


Yet, for the monetary value of one advanced surgical robot - around �12 million - a quarter of a million children can be treated and given the ability to walk again.


Unlike expensive high tech surgery, Mr Mannion establish a simple solution within the reach of more than than a small percentage of the world's population.


The first of three Superdoctors programmes in the series is scheduled to black market on Thursday 21 August on BBC One at 2100BST.




More info

Saturday, 23 August 2008

Bavarian Nordic Announces Partnership With National Cancer Institute In The US And Obtains Rights To A New Vaccine Candidate

�Bavarian Nordic's US subsidiary company, BN ImmunoTherapeutics has entered into a scientific partnership with the National Cancer Institute (NCI) in the United States. Under the Cooperative Research and Development Agreement (CRADA) the NCI and Bavarian Nordic will jointly develop new immunotherapies for the treatment of prostate cancer. Under the CRADA, BN ImmunoTherapeutics has rights to exclusively licence intellectual attribute that results from this collaboration.



Bavarian Nordic testament in the future explore opportunities for extending this collaboration to further develop its cancer projects. By combining Bavarian Nordic's expertness within cancer vaccine development with one of the world's starring centres of excellence inside cancer research, the company is confident that this collaboration will result in new and innovative solutions to a disease orbit with high gear unmet medical needs as well as expand and accelerate Bavarian Nordic's cancer the Crab activities.



Through the quislingism and a license concord with the United States Public Health Service, the company has obtained rights to intellectual property rights covering a prostate cancer vaccine ware candidate in late phase II clinical development. Data from key clinical studies with this vaccine campaigner are currently being evaluated. Later in 2008 the company will inform the market about how this development image will have a future in the pipeline of Bavarian Nordic.

About the NCI


The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH) and is the United States federal government's preeminent cancer inquiry organization.



- The National Cancer Institute (NCI) has played an active role in the development of drugs for cancer handling for over 50 long time. This is reflected in the fact that or so one half of the chemotherapeutic drugs currently used by oncologists for cancer treatment were discovered and/or developed at NCI.


- NCI has supported the research efforts of at least 20 Nobel Prize winners. For approximately half of these Nobel laureates, NCI supported the awarded research.


- According to a 1996 NCI analysis of drugs approved by the FDA, two-thirds of the antitumour drugs approved as of the end of 1995 were NCI-sponsored Investigational New Drugs.



The collaboration with the NCI does non change Bavarian Nordic's antecedently announced financial guidance for 2008.



Anders Hedegaard, President & CEO of Bavarian Nordic, commented:


"I am very happy to see that we are consolidating our firm relationships within the US. The NCI relationship opens up for us new and exciting opportunities inside the force field of cancer and we are proud to join forces with one of the most prestigious and well-established cancer research organisations in the world. In the collaboration with NCI Bavarian Nordic benefits from the tremendous expertise in cancer therapeutics development that is confront in the NCI organization. This will truly strengthen cancer as a strategic focus domain in years to issue forth, in short letter with our outlined strategy."

About Bavarian Nordic


Bavarian Nordic A/S is a leading industrial biotech company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical pauperism. The company's business scheme is focused in three areas: biodefence, cancer and infectious diseases. Bavarian Nordic's proprietary and patented applied science MVA-BN� is one of the world's safest, multivalent vaccine vectors. Bavarian Nordic has ongoing contracts with the US government for the late-stage development and procurement of the company's third-generation variola vaccine, IMVAMUNE�.


Bavarian Nordic is listed on the OMX Nordic Exchange Copenhagen under the symbolization BAVA.

Bavarian Nordic


More info

Wednesday, 13 August 2008

Start Of Phase 2b Right-heart Catheter Study Of PRX-08066 In Patients With Chronic Obstructive Pulmonary Disease And Moderate-To-Severe PH

�EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and development novel therapeutics through the use of its proprietary and highly efficient in silico dose discovery platform, announced that it has initiated its Phase 2b right-heart catheter study of PRX-08066 in patients with chronic obstructive pulmonary disease (COPD) and moderate-to-severe pulmonary hypertension (PH). PRX-08066 is a novel serotonin type 2B sense organ (5-HT2B) opposer that crataegus laevigata represent a new mechanics of action for treating PH.


"There are presently no sanctioned drugs to treat PH associated with COPD and it is estimated that this disease may affect up to six 1000000 people worldwide," said Elkan Gamzu, Ph.D., interim top dog executive ship's officer of EPIX. "These patients have a very poor prognosis and, consequently, in that respect is a significant unmet medical indigence for an effective treatment. We believe that PRX-08066 may be the only 5-HT2B opposer being highly-developed for pulmonic hypertension that has the potential to selectively and safely reduce pulmonary arteria blood pressure in these patients without affecting their systemic blood pressure."


"There is an undeniable need for safe and efficient treatments for patients with PH associated with COPD," said Aaron Waxman, M.D., Ph.D., helper professor of medicine, Harvard Medical School and Massachusetts General Hospital, Pulmonary and Critical Care Medicine and lead investigator of this Phase 2b study. "We believe this drug english hawthorn be an important advance toward effective treatment for patients with this progressive lung disease, and hope to see reductions in pulmonary artery blood atmospheric pressure and improvements in exercise capacity in this trial similar to those seen in previous trials with PRX-08066 victimisation more stringent techniques."


This single-arm, open-label, Phase 2b study is designed to evaluate the mean pulmonic artery ancestry pressure change from baseline as measured directly by right-heart catheterization and will also bar the change from baseline in the standard six-minute walk length test afterwards three months of handling. Patients volition be treated with 500 mg of PRX-08066 on day peerless of the trial followed by twice-daily dosing of 300 mg of PRX-08066 for ternion months. The trial is designed to enroll adult patients with COPD and moderate-to-severe PH.


PRX-08066 may represent a novel mechanism for selectively dilating pathologic pulmonary arteries without affecting systemic line of descent pressure. Expression of the 5-HT2B receptor is increased in the pulmonary arteries of patients with PH. Blocking the 5-HT2B receptor in patients with PH may reduce or forestall the acute rise in pulmonary blood pressures which occurs when patients increase their activity. This mechanics means that the tenderness would do less work for a given grade of activity, allowing for improvements in exercise tolerance. Moreover, by blocking the serotonin-dependent outgrowth of pneumonic vascular smooth muscle cells, which farther increases pulmonary blood pressures and increases workload need on the heart, PRX-08066 could potentially slow the progression of PH. Over time, this effect could translate into long-term improvements in exercise tolerance and slowing of the vascular and cardiac remodeling that leads to right heart failure. These kinds of effects have been seen with PRX-08066 in presymptomatic animal models of hypoxia-induced pulmonary hypertension.


COPD is a progressive lung disease that affects nearly 30 million people worldwide and is characterized by air flow obstruction which interferes with normal breathing and impairs the ability to example and perform daily activities. According to a December 2005 Datamonitor report, PH is estimated to be present in up to 20 percentage of patients with COPD. Despite the fact that patients with COPD and concomitant moderate-to-severe PH broadly speaking have poor prognoses, on that point are no agents presently approved to treat this patient population.

About PRX-08066


Discovered and designed using EPIX's proprietary G-protein coupled receptor (GPCR) mould and optimisation technology, EPIX is developing PRX-08066 to provide both symptomatic improvement of PH, through selective dilation of diseased pulmonary arteries, and to likewise slow disease progression by inhibiting the serotonin-mediated node of the pulmonary arterial blood vessel vessels. EPIX believes PRX-08066 may be a first-in-class selective antagonist of the 5-HT2B sensory receptor for the treatment of PH.


In a Phase 2a, randomized, double-blind, placebo-controlled trial of 71 patients, 62 of whom were evaluable, treatment with PRX-08066 resulted in statistically important (p=0.043) reductions in median systolic pulmonary artery pressure (SPAP) compared with placebo subsequently two weeks of treatment. Responder (defined as greater than or equal to a 4mmHg drop in SPAP) rates were 45% on cd mg of PRX-08066 given once-daily vs. 14% on placebo. The company has also completed several Phase 1 trials with PRX-08066 in respectable volunteers, including a Phase 1b study that assessed the personal effects of PRX-08066 on pulmonary artery rakehell pressure in athletes whose pulmonary pressures were increased by picture to a reduced oxygen level (hypoxia). The results of this Phase 1b trial indicated that two hundred mg of PRX-08066 tending orally double daily importantly reduced the increase in pulmonary arterial blood vessel blood pressure during hypoxic exercise (by 3.6mmHg vs. placebo), without affecting systemic blood press. The half life of PRX-08066 is approximately 20 hours and the broker has shown good oral absorption. PRX-08066 was well-tolerated when given alone and when combined with standard medications for COPD patients as all of the patients in the Phase 2a test were on several concomitant medications. One patient in the four hundred mg dosage group world Health Organization continued into the six-week open-label extension experienced a modest addition in liver enzyme levels at the end of the filename extension that was believed to be drug-related. These values returned to normal within two weeks and the patient remained asymptomatic.

About EPIX


EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly effective in silico drug find platform. The company has a line of internally-discovered drug candidates currently in clinical development to handle diseases of the central nervous system and lung conditions. EPIX also has collaborations with leading organizations, including GlaxoSmithKline, Amgen, Cystic Fibrosis Foundation Therapeutics and Bayer Schering Pharma.



This news release contains extract or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on current expectations of direction. These statements relate to, among former things, our expectations regarding our Phase 2b study of PRX-08066 in patients with COPD and moderate-to-severe PH and the potency efficacy of PRX-08066. These statements are neither promises nor guarantees, but are subject to a sort of risks and uncertainties, many of which ar beyond our control, and which could cause existent results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things: risks that PRX-08066 may bomb in the clinic or may not be successfully marketed or manufactured; risks relating to our power to boost the ontogenesis of PRX-08066; failure to obtain the financial resources to complete development of PRX-08066; our inability to achieve commercial success for our products and technologies; our loser to follow with regulations relating to our products and cartesian product candidates, including FDA requirements; the risk that FDA may interpret the results of our studies differently than we hold; and risks of fresh, changing and competitive technologies and regulations in the U.S. and internationally. Existing and prospective investors are cautioned not to space undue reliance on these forward-looking statements, which speak only as of the date hereof. We take on no obligation to update or retool the information contained in this press release, whether as a result of new information, future events or fate or other than. For additional information regarding these and other risks that we face, attend the revelation contained in our filings with the Securities and Exchange Commission, including our most late Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.

EPIX Pharmaceuticals


More information

Wednesday, 6 August 2008

Michael Armstrong

Michael Armstrong   
Artist: Michael Armstrong

   Genre(s): 
Other
   Easy Listening
   



Discography:


Rockabye Baby No Doubt   
 Rockabye Baby No Doubt

   Year: 2007   
Tracks: 11


Rockabye Baby!: Lullaby Renditions Of Coldplay   
 Rockabye Baby!: Lullaby Renditions Of Coldplay

   Year: 2006   
Tracks: 10


Rockabye Baby! Lullaby Rendi..   
 Rockabye Baby! Lullaby Rendi..

   Year:    
Tracks: 11




 






Thursday, 26 June 2008

Max Corbacho & Bruno Sanfilippo

Max Corbacho & Bruno Sanfilippo   
Artist: Max Corbacho & Bruno Sanfilippo

   Genre(s): 
Ambient
   



Discography:


Indalo   
 Indalo

   Year: 2004   
Tracks: 7




 





Jr. Hank Williams

Thursday, 19 June 2008

Brannan Lane and Nature

Brannan Lane and Nature   
Artist: Brannan Lane and Nature

   Genre(s): 
Ambient
   



Discography:


Sleep Cycle   
 Sleep Cycle

   Year: 1999   
Tracks: 9




 






Wednesday, 11 June 2008

The Daily Trailer: Get Smart

One of the most popular television shows of the sixties is getting a big screen update, with Steve Carell taking on the role of Agent 86 Maxwell Smart while Anne Hathaway plays Agent 99 in the new 'Get Smart' movie. Watch the trailer here.


NEXT:  Rupert Everett Apologizes For Army Insult

Photo courtesy of Warner Bros. 



Wednesday, 4 June 2008

P Diddy Denies Romancing Cameron Diaz

Sean ‘Diddy’ Combs has blasted reports that he is dating Cameron Diaz, stating that the rumours are “ridiculous”.

The two have been spotted together a numerous amount of times, and looked close at Sunday night's MTV Movie Awards in California.

But Combs insists their friendship is innocent and completely platonic.

He tells the New York Daily News: "It is ridiculous that two celebrities of the opposite sex can't just hang out with a group of friends without it being reported as more than that. We are just friends."

Diaz, who has been single since splitting with Justin Timberlake, recently revealed she is active on the dating scene, explaining: "Men are the best, sex is the best."
Do you think Cameron and Diddy make a cute couple? Be sure to leave your comments below.

Saturday, 24 May 2008

'Bigger, Stronger, Faster*' Explores Steroid Use -- And Claims They're Not As Harmful As We Think




Every so often, a movie comes along that feels like a backscratcher that's been handed to moviegoers just in time to relieve their collective itch.

From "Super Size Me" to "My Big Fat Greek Wedding," "Fahrenheit 9/11" to "The Passion of the Christ," each hoped to connect with specialized audiences but ended up appealing to millions more, simply because they were in the right place at the right time. Now, a soon-to-be-released flick is gaining muscular momentum, thanks in no small part to recent headlines.

"This film is an exploration of America's win-at-all-costs culture during the current steroid issue in America but also the steroid issue that has been in my family for the past 15 years," burly debut filmmaker Chris Bell said about his documentary "Bigger, Stronger, Faster*," scheduled for release May 30. "My brother and I were always power-lifters. My older brother was a great football player, and he went off to play football at a Division I college. In the first week he was there, he started using steroids in order to perform better. ... Later on, we ended up going down that path as well. We had this feeling that we weren't good enough — we had to take it to the next level."

In the tradition of Michael Moore and Morgan Spurlock, Bell cast himself as the earnest, wisecracking host of this exploration into the dark side of America's obsession with becoming bigger, stronger and faster. The flick was unveiled to heavy buzz at the Sundance Film Festival, and as names like Bonds, Stallone and 50 Cent have dominated headlines with steroid accusations, the public's hunger for the film has continued to develop.

"I grew up watching Hulk Hogan, Sylvester Stallone and Arnold Schwarzenegger — those guys were my heroes," he said of the flick, which features archival footage of the young Bell brothers dressing up as wrestlers and practicing Hogan's finishing moves on each other. "At some point, I found out that all my heroes took steroids to get to where they are. In my mind, I was asking the question: 'When you find out that all your heroes did steroids, do you follow the rules, or do you follow your heroes?' "

And this is where "BSF*" truly becomes a documentary on steroids — in all senses. One moment, Bell is hilariously being transformed into a before/after photo; the next, he's breaking the news to his in-denial mother that her boys have abused performance-enhancing drugs. Keeping an open mind while asking the viewer to do the same, he often finds that steroids aren't as dangerous as we've been informed they are.

"We worked on the movie for three years. We completely fact-checked the movie up and down to make sure everything was correct," said the star, who even goes so far as to hunt down the Governator in his search for the truth. "I have to say to kids out there that steroids are not for kids ... [but] you'll find that anabolic steroids are actually very safe in adult males over the age of 25. That's where all the studies have been done. There's always a difference between use and abuse, and if you're taking too much of anything, you're going to harm your body in different ways. But honestly, it's considered very safe among adult males — much safer than smoking or drinking alcohol.

"Does 50 Cent need growth hormone?" he asked, referring to recent allegations that the rapper took steroids. "Probably not. But there are a lot of drugs that we don't physically need. Viagra is one of the most-prescribed drugs in America. If you want a drug, and there is a legal way to get it, you should be able to get it and be protected by the law. And that's not what's happening now."

Naturally, such statements will enrage some people. But Bell wants moviegoers to be entertained by his movie and also to think twice before they condemn Bonds or blame last year's Chris Benoit tragedy on the wrestler's " 'roid rage."

"I definitely see signs that [Barry Bonds and Roger Clemens] did use steroids," he explained. "But is the athlete guilty because of their own competitive drive?

"Roger Clemens and Barry Bonds were making millions of dollars before. It's not about making more millions of dollars: It's an ego thing," he insisted. "It's a competitive drive that every athlete has."

And one which Bell and his brothers succumbed to as well, in their quest to become like Schwarzenegger, Stallone and Hogan — three men who have since admitted to steroid abuse. "In my case, I tried steroids, and I stopped using them because I felt it was immoral," Bell explained, shaking his head. "This film was a personal exploration for me of why I feel guilty. ... You want to spark a national debate. I want to get people talking. I want to put the issue that's always been under the table up on the table and have people talk about it in a more intellectual way."

Check out everything we've got on "Bigger, Stronger, Faster*."

For breaking news, celebrity columns, humor and more — updated around the clock — visit MTVMoviesBlog.com.






See Also

Sunday, 18 May 2008

More awards for Oscar-tipped Atonement

More awards for Oscar-tipped Atonement



Period drama 'Atonement' has picked up another host of awards in advance of the Oscars.
It received four prizes at the inaugural Richard Attenborough Film Awards: Best Film, Film-Maker of the year for director Joe Wright, Actor of the Year for James McAvoy and Screenwriter of the Year for Christopher Hampton.
'Atonement' star Keira Knightley missed out on the Best Actress award, which went instead to Cate Blanchett for 'Elizabeth: The Golden Age'.
Sam Riley was named Rising Star of the Year for his breakthrough performance as Joy Division frontman Ian Curtis in 'Control'.
At the ceremony, host Richard Attenborough said: "The last year has shown cinema to be both resilient and innovative, with large audiences eager to enjoy the unique theatrical experience."
He added: "It has also brought a superb crop of terrific films with compelling performances from both experienced and fresh talents. I offer my warmest congratulation to this admirable set of winners."
'Atonement', an adaptation of Ian McEwan's bestselling novel, has been nominated for seven Oscars, including Best Picture and Best Supporting Actress for 13-year-old Irish actress Saoirse Ronan.
It is in contention for 14 awards at the BAFTAs, which will take place on Sunday 10 February.




Planisphere

Monday, 5 May 2008

Eddie Murphy marries film producer

Eddie Murphy marries film producer



It is reported that Eddie Potato married film producer Tracey Edmonds on a buck private island in French people Polynesia yesterday.
People magazine reports that the ceremony took shoes away Bora Bora and was attended by 25 guests.
Spud divorced his wife of 13 long time, Nicole, in 2006. The duad had basketball team children.
Edmonds was previously married to R&B





Wednesday, 30 April 2008

Winehouse helps Ronson through break-up

Winehouse helps Ronson through break-up



Isaac Bashevis Singer Amy Winehouse is serving DJ and player Bell ringer Ronson to catch through and through the recent epoch take apart of a long-term kinship.
According to The Mirror, Ronson said that his friend has been very supportive towards him in recent epoch weeks.
The 32-year-old DJ said: "It's sad multiplication for me at the moment. I was geological dating my girlfriend for three days simply we split up."
"I'm lucky I have good friends. Amy has been brilliant and is always on that point for me - and I'm thither for her to a fault."
However, Ronson was quick to deny rumours of romance betwixt the twin, saying: "no theory".
He added: "I am sick of talking about it. Amy is a friend."





Thursday, 24 April 2008

Pissing Razors

Pissing Razors   
Artist: Pissing Razors

   Genre(s): 
Metal
   



Discography:


Evolution   
 Evolution

   Year: 2003   
Tracks: 10


Where We Come From   
 Where We Come From

   Year: 2001   
Tracks: 10


Fields Of Disbelief   
 Fields Of Disbelief

   Year: 2000   
Tracks: 12


Cast Down The Plague   
 Cast Down The Plague

   Year: 1999   
Tracks: 13


Pissing Razors   
 Pissing Razors

   Year: 1998   
Tracks: 13




Heavy metallists Pissing Razors come from El Paso, TX, and ar musically like to local heroes Pantera, addition Skinlab and Machine Head -- in other language, angst-filled, shouted vocals ar integrated with meaty guitar riffs for a sound that's custom-built for the thrash colliery. Singer Joe Rodriquez, bassist Rick Valles, and drummer Eddy Garcia have appeared on all trey of the group's albums so far, 1998's self-titled release, 1999's Cast Down the Plague, 2000's Fields of Disbelief, and 2001's Where We Come From, with guitar player Matt Lynch appearing on the first-class honours degree deuce albums and Cesar Soto on the last deuce. In February of 2001, Rodriquez left wing the chemical group.






Tuesday, 15 April 2008

Russell up for Brand new gong

Russell up for Brand new gong




CHRIS MOYLES and comedian A.E. Make own been nominated for gongs at this
year's Sony Wireless Academy Awards.

The Oscars of the wireless industry will pick up the Wireless 1 epipactis gigantea battling it
come out with ahead of time good morning rival Johnny Sarah Vaughan for the Breakfast Show
Laurels.

Former Big Brother's Big Sassing conferrer A.E. - world Health Organization launched his Sabbatum
late-night Radio 2 show in 2006 - is nominated in the Amusement
category.

Radiocommunication 2 star Jonathan Sir Ronald Ross must fight away contender from the likes of ZANE
LOWE and Heart star JAMIE THEAKSTON to win the prize for Medicine
Radio Personality of the Year.

The 26th Sony Radio Academy Awards takes place on May 12 at the Grosvenor
Planetary house Hotel in Capital of the United Kingdom.

The nominations are:

Breakfast Usher Award

Five Survive Breakfast - BBC News Programmes for Five-spot Live on

Bowie@Breakfast - Wireless Clyde

Majuscule Breakfast with Greyback Vaughan - Capital 95.8

Jo & Twiggy Breakfast Usher -




Dave Hole